Document Detail


Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.
MedLine Citation:
PMID:  8418268     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A novel 99mTc complex (1,2-bis[bis(2-ethoxyethyl)phosphino] ethane, 99mTc-tetrofosmin) has been developed to replace 201Tl in myocardial perfusion imaging. Biodistribution, safety and dosimetry of 99mTc-tetrofosmin were studied in 12 male volunteers, each at rest and during exercise. Safety parameters measured to 48 hr postinjection revealed no clinically significant long-term drug-related changes. Biodistribution was studied by acquiring whole-body or serial static images up to 48 hr postinjection. Technetium-99m-tetrofosmin shows good heart uptake (1.2%) with retention. Clearance is excellent from blood (< 5% by 10 min), liver (< 4.5% by 60 min) and lung. Sequestration of activity by skeletal muscle is enhanced during exercise. Radiation dosimetry calculations indicate that the effective dose, assuming a 3.5 hr bladder voiding period, is 32.9 x 10(-3) rad/mCi (8.9 x 10(-3) mSv/MBq) at rest and 26.7 x 10(-3) rad/mCi (7.1 x 10(-3) mSv/MBq) after exercise. Technetium-99m-tetrofosmin can produce high quality myocardial images from 5 min to several hours postinjection.
Authors:
B Higley; F W Smith; T Smith; H G Gemmell; P Das Gupta; D V Gvozdanovic; D Graham; D Hinge; J Davidson; A Lahiri
Related Documents :
3324058 - The use of intravenous dipyridamole in thallium 201 myocardial perfusion imaging.
2806328 - The contraction fraction (cf) in myocardial studies with technetium-99m-isonitrile (mib...
7865548 - Effects of exercise-induced alterations of cardiac physiology on nuclear perfusion imag...
25249278 - A review on the mechanisms of blood-flow restriction resistance training-induced muscle...
1982608 - Alpha-adrenergic regulation of myocardial performance in the exercising dog: evidence f...
14555668 - High-speed running performance: a new approach to assessment and prediction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  34     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  1993 Jan 
Date Detail:
Created Date:  1993-02-03     Completed Date:  1993-02-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  30-8     Citation Subset:  IM    
Affiliation:
Pharmaceuticals R&D, Amersham International plc, Buckinghamshire, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heart / radionuclide imaging*
Humans
Male
Metabolic Clearance Rate
Middle Aged
Organophosphorus Compounds / adverse effects,  diagnostic use,  pharmacokinetics*
Organotechnetium Compounds / adverse effects,  diagnostic use,  pharmacokinetics*
Radiation Dosage
Tissue Distribution
Chemical
Reg. No./Substance:
0/Organophosphorus Compounds; 0/Organotechnetium Compounds; 0/technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid subtrac...
Next Document:  Human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy.